Imagenebio, INC. (IMA) — 8-K Filings

8-K Filings (23)

• 8-K Filing — Apr 13, 2026
• ImageneBio, Inc. Reports Board and Executive Compensation Changes — Dec 18, 2025 Risk: medium
  ImageneBio, Inc. announced on December 12, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company reported
• ImageneBio, Inc. Files 8-K — Nov 19, 2025 Risk: low
  ImageneBio, Inc. filed an 8-K on November 19, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known a
• 8-K Filing — Nov 5, 2025
• ImageneBio Reports Material Agreement Entry & Termination — Oct 29, 2025 Risk: medium
  ImageneBio, Inc. (formerly Ikena Oncology, Inc.) filed an 8-K on October 29, 2025, reporting on events that occurred on October 23, 2025. The filing indicates b
• ImageneBio Reports Director/Officer Changes & Compensation Updates — Oct 22, 2025 Risk: medium
  ImageneBio, Inc. filed an 8-K on October 22, 2025, reporting changes effective October 21, 2025. The filing indicates a departure of directors or certain office
• ImageneBio, Inc. Reports Leadership Changes and Compensation Updates — Oct 10, 2025 Risk: medium
  On October 10, 2025, ImageneBio, Inc. filed an 8-K report detailing changes in its leadership and executive compensation. The filing indicates the departure of
• ImageneBio Changes Certifying Accountant to 03 Life Sciences — Aug 5, 2025 Risk: low
  ImageneBio, Inc. (formerly Ikena Oncology, Inc.) announced on August 2, 2025, a change in its certifying accountant to 03 Life Sciences. This change was effecti
• ImageneBio Appoints Dr. David R. Walt to Board — Aug 1, 2025 Risk: low
  ImageneBio, Inc. announced on July 28, 2025, a change in its board of directors. Dr. David R. Walt has been appointed as a Class II director, effective immediat
• ImageneBio Reports Multiple Material Events — Jul 29, 2025 Risk: medium
  ImageneBio, Inc. (formerly Ikena Oncology, Inc.) filed an 8-K on July 29, 2025, reporting several material events. These include entering into a material defini
• Imigenebio, Inc. Changes Name from Ikena Oncology, Inc. — Jul 25, 2025 Risk: low
  On July 25, 2025, Imigenebio, Inc. (formerly Ikena Oncology, Inc.) filed an 8-K report. The company, incorporated in Delaware, is located at 12526 High Bluff Dr
• Ikena Oncology Files 8-K Report — Jul 24, 2025 Risk: low
  On July 24, 2025, Ikena Oncology, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transac
• Ikena Oncology Files 8-K: Other Events Reported — Jul 22, 2025 Risk: medium
  On July 22, 2025, Ikena Oncology, Inc. filed an 8-K report. The filing indicates an "Other Events" item, suggesting a significant development not covered by oth
• Ikena Oncology Reports Director Changes and Executive Compensation Adjustments — Jul 16, 2025 Risk: medium
  On July 15, 2025, Ikena Oncology, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a depart
• Ikena Oncology Files 8-K on Officer/Director Changes — Jul 15, 2025 Risk: medium
  On July 15, 2025, Ikena Oncology, Inc. filed an 8-K report detailing several key events. These include the departure of directors or certain officers, the elect
• Ikena Oncology Files 8-K Report — Jul 11, 2025 Risk: low
  On July 11, 2025, Ikena Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating upd
• Ikena Oncology Files 8-K Report — Jul 1, 2025 Risk: low
  On July 1, 2025, Ikena Oncology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Ex
• Ikena Oncology Files 8-K: Material Agreements, Control Changes — Dec 23, 2024 Risk: medium
  On December 23, 2024, Ikena Oncology, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement
• Ikena Oncology Appoints New Chief Medical Officer — Jul 12, 2024 Risk: medium
  Ikena Oncology, Inc. announced on July 8, 2024, the appointment of Dr. Jeffrey W. Almasleh as Chief Medical Officer. Dr. Almasleh brings extensive experience in
• Ikena Oncology Reports on Shareholder Vote — Jun 10, 2024 Risk: low
  Ikena Oncology, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders on June 7, 2024. The filing details the company
• Ikena Oncology Terminates Bristol Myers Squibb Deal for IK-750 — May 28, 2024 Risk: medium
  On May 23, 2024, Ikena Oncology, Inc. announced the termination of its collaboration and license agreement with Bristol Myers Squibb for the development of IK-7
• Ikena Oncology Reports Executive Changes and Compensation Arrangements — Feb 21, 2024 Risk: medium
  Ikena Oncology, Inc. filed an 8-K on February 21, 2024, reporting an event on February 20, 2024. The filing primarily concerns the departure of directors or cer
• Ikena Oncology Relocates HQ to 50 Northern Ave, Cuts Costs — Jan 18, 2024
  Ikena Oncology, Inc. filed an 8-K on January 17, 2024, to report that it is closing its office at 645 Summer Street, Suite 101, Boston, Massachusetts 02210, and

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX